Jason Kolbert, Maxim Group, and Les Funtleyder, ESquared, discuss biotech opportunities in Cuba post-Castro.
Thernos is being sued for alleged fraud by Robert Colman, Robertson Stephens co-founder. CNBC's Sue Herera reports.
Alex Tarrant, assistant editor at Dealreporter Europe, weighs in on Johnson & Johnson's proposed acquisition of Swiss biotechnology company Actelion.
Robyn Karnauskas, Citi Research lead biotech analyst, weighs in on the drop in Juno Therapeutics following the company's study halt.
The “Fast Money Halftime Report” traders weigh in on the biotech sector, with Eli Lilly and Juno Therapeutics stocks dropping significantly.
If they're right, the average lifespan of 79 years will be a thing of the past, and humans could live for decades longer.
CNBC's Meg Tirrell reports the latest surrounding the Valeant and Philidor controversy. CNBC's Kate Kelly and David Winters, Wintergreen Advisors CEO, weigh in on Valeant's stock.
Amgen's migraine drug meets its clinical trial goal. CNBC's Meg Tirrell reports.
CNBC's Meg Tirrell on the latest regarding data on how a Puma drug designed to treat breast cancer shows gastric side effects.
Top-ranking health care analyst & senior analyst at Evercore ISI, Umer Raffat discusses biotech stocks on Power Lunch.
Les Funtleyder, ESquare portfolio manager, shares his take on the healthcare sector amid a Trump presidency.
CNBC's Meg Tirrell reports details from Mylan's earnings conference call. The "Fast Money" traders weigh in.
The political pressure on drug stocks has faded with Donald Trump's election win and voter rejection of a California ballot initiative on pricing.
Analysts expected Mylan to report earnings of $1.45 per share on revenues of $3.12 billion, according to a Thomson Reuters consensus estimate.
CNBC’s Meg Tirrell discusses the surge in biotech and pharmaceuticals following Trump’s victory, as well as what investors expect from here.
Shares of health insurers and hospitals got a lift Tuesday, but the rally doesn't extend to battered biotech and pharmaceutical stocks.
Valeant shares were down 22 percent on Tuesday, but Wells Fargo's David Maris says the company still has some time to right the ship.
CNBC's Meg Tirrell takes a closer look at investor sentiment in the biotech sector ahead of the presidential election, including best-positioned stocks according to analysts. The "Fast Money" traders weigh in.
Greg Zuckerman, WSJ reporter, discusses how the plunge in biotech contributed to a $26 billion loss in hedge fund Paulson & Co.
Bill George, Harvard Business School Professor and former Medtronic Chairman and CEO, and David Maris, Wells Fargo Securities Specialty Pharmaceutical Analyst, weigh in on the ongoing drug-pricing war.